Company intelligence / Profile preview

Guangzhou Fanhoutang Pharmaceutical

Ownership: Private
Development stage: Other

Overview

The company’s lead asset, Bailing Tongfengxiao Granules, has reached Phase 2 clinical trials for arthritis and gouty arthritis. No published clinical results are available in the public domain as of June 2025.

There are no additional programs or late-stage assets reported.

The company appears to focus on herbal/traditional Chinese medicine approaches for chronic inflammatory and metabolic conditions.

No information on FDA/CFDA approvals or commercialized products was found.

No evidence of international expansion or global regulatory filings.

Therapeutic areas: EndocrinologyRheumatologyRare DiseasesDermatology
Modalities: Herbal medicineSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Guangzhou Fanhoutang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Fanhoutang Pharmaceutical.

Explore the full profile